Machine perfused livers versus cold storage

27 June 2014  //  Clinical Evidence

This is the first prospective clinical study to examine hypothermic machine perfusion (HMP) for liver transplantation. Investigators used an early prototype of LifePort Liver Transporter to compare HMP to a matched group of transplanted static cold storage livers. Outcomes were recorded for 12 months post-transplant. Primary endpoints included mean incidences of primary non-function, early allograft dysfunction and patient and graft survival at 1 month and 1 year.

Key results

Results showed 50% fewer patients receiving HMP livers had biliary complications and a total of 25% of cold stored livers showed early allograft dysfunction compared with 5% of HMP livers (p=0.08). Data also showed a significantly lower length of hospital stay in patients receiving LifePort perfused livers than cold storage livers (10.9 ± 4.7 days vs. 15.3 ± 4.9 days; p=0.006).

The authors concluded that HMP is safe, may improve graft function and attenuates classical biochemical markers of liver preservation injury. The data warrant future large-scale multicenter studies of HMP in liver transplantation.

Reference

Guarrera JV, et al. Am J Transplant 2010;10:372–381.